Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Buy” by Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned a consensus recommendation of “Buy” from the ten research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $20.89.

YMAB has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating on shares of Y-mAbs Therapeutics in a research note on Wednesday, December 11th. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 price target for the company. Finally, Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target on the stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its holdings in shares of Y-mAbs Therapeutics by 8.0% in the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock valued at $1,461,000 after purchasing an additional 8,974 shares during the period. Rice Hall James & Associates LLC increased its holdings in Y-mAbs Therapeutics by 4.2% in the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock worth $1,084,000 after buying an additional 3,589 shares during the period. Massachusetts Financial Services Co. MA raised its position in Y-mAbs Therapeutics by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock worth $993,000 after buying an additional 2,760 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after acquiring an additional 65,732 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Y-mAbs Therapeutics in the second quarter worth $297,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Price Performance

NASDAQ:YMAB opened at $7.39 on Friday. Y-mAbs Therapeutics has a 1-year low of $6.92 and a 1-year high of $20.90. The company has a 50-day moving average of $10.62 and a 200 day moving average of $12.20. The firm has a market cap of $330.99 million, a PE ratio of -13.69 and a beta of 0.69.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the prior year, the business posted ($0.18) earnings per share. Sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.66 EPS for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.